<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04566874</url>
  </required_header>
  <id_info>
    <org_study_id>SPA-2018</org_study_id>
    <nct_id>NCT04566874</nct_id>
  </id_info>
  <brief_title>SPIRA™-A 3D and HCT/p DBM vs. Medtronic Divergent™-L/Perimeter™ and Recombinant BMP-2</brief_title>
  <official_title>SPIRA™-A 3D Printed Titanium Anterior Lumbar Interbody Fusion Device and HCT/p Demineralized Bone Matrix Versus Medtronic Divergent™-L/Perimeter™ PEEK Anterior Lumbar Interbody Fusion Device and Recombinant Bone Morphogenic Protein-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Camber Spine Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Camber Spine Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, randomized, controlled clinical evaluation utilizing the SPIRA™ ALIF 3-D&#xD;
      printed titanium interbody device with DBM vs a Medtronic PEEK ALIF interbody device with BMP&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single blinded randomized 1:1, controlled, prospective clinical study to evaluate&#xD;
      fusion status and patient reported outcomes in circumferential lumbar fusion between L2-S1 at&#xD;
      a single level with posterior screw fixation (Camber Spine Orthros System) and anterior&#xD;
      surgery consisting of one of the treatment groups: subjects treated with the SPIRA™-A&#xD;
      Interbody Device and HCTP/p DBM or subjects treated with Medtronic Divergent-L or Perimeter™&#xD;
      PEEK ALIF Interbody Device and rhBMP-2 (6mg per level).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2020</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>single blind randomized 1:1</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>subjects will be blinded prior to surgery. Following surgery, maintaining masking may not be feasible as subjects will have access to medical records and/or radiographs.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Radiographic Fusion</measure>
    <time_frame>6 months</time_frame>
    <description>AP/Lateral, Flexion, Extension and CT radiographs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic Fusion</measure>
    <time_frame>12 months</time_frame>
    <description>AP/Lateral, Flexion, Extension and CT radiographs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiographic Fusion</measure>
    <time_frame>24 months</time_frame>
    <description>AP/Lateral, Flexion, Extension and CT radiographs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Oswestry Disability Index</measure>
    <time_frame>up to and including 24 months</time_frame>
    <description>Improvement in the ODI as measured by a minimum of a 15 point improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Back and Leg VAS</measure>
    <time_frame>up to and including 24 months</time_frame>
    <description>Improvement in the VAS as measured by a minimum of a 20 point improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VR-12 Health Survey</measure>
    <time_frame>up to and including 24 months</time_frame>
    <description>Improvement in the VR-12 Health Survey as demonstrated by pre-op and post-op evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PROMIS score</measure>
    <time_frame>up to and including 24 months</time_frame>
    <description>Change in the PROMIS score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Degenerative Disc Disease</condition>
  <condition>Spinal Stenosis</condition>
  <condition>Spondylolisthesis</condition>
  <condition>Scoliosis</condition>
  <arm_group>
    <arm_group_label>Spira-A with HCT/p DBM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Single level Spira-A 3D printed Titanium ALIF Device with HCT/p DBM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medtronic PEEK ALIF with Infuse</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single level Medtronic Divergent-L/Perimeter PEEK ALIF Device with Recombinant Bone Morphogenic Protein-2 (Infuse)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ALIF</intervention_name>
    <description>Anterior Lumbar Interbody Fusion</description>
    <arm_group_label>Medtronic PEEK ALIF with Infuse</arm_group_label>
    <arm_group_label>Spira-A with HCT/p DBM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  skeletally mature adults&#xD;
&#xD;
          -  completed 6 month non-operative or conservative therapy&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
          -  back pain with radicular symptoms as evidenced by leg pain&#xD;
&#xD;
          -  Degenerative Disc Disease involving a single level between L2 and S1&#xD;
&#xD;
          -  subject willing to participate in study and follow protocol&#xD;
&#xD;
          -  subject willing to comply with Post-op management program&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  systemic infection such as AIDS, HIV or Active hepatitis&#xD;
&#xD;
          -  autoimmune disease&#xD;
&#xD;
          -  significant metabolic disease that might compromise bone growth&#xD;
&#xD;
          -  history of malignancy&#xD;
&#xD;
          -  previous surgery for primary tumor, trauma or infection&#xD;
&#xD;
          -  subject requires 2 or more levels of fusion&#xD;
&#xD;
          -  previous spinal instrumentation or previous interbody fusion at involved level&#xD;
&#xD;
          -  spondylolisthesis of grade greater than/equal to 2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Kaye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rothman Orthopaedic Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Donald W Guthner, BS</last_name>
    <phone>646.460.2984</phone>
    <email>dguthner@cambermedtech.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Noel Hetrick</last_name>
    <email>nhetrick@cambermedtech.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rothman Orthopaedic Institure</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Kaye, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Back Institute</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Rusch, CCRC</last_name>
      <phone>972-608-5143</phone>
      <email>srusch@texasback.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 17, 2020</study_first_submitted>
  <study_first_submitted_qc>September 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>September 23, 2020</last_update_submitted>
  <last_update_submitted_qc>September 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lumbar spinal fusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scoliosis</mesh_term>
    <mesh_term>Spinal Stenosis</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
    <mesh_term>Spondylolisthesis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>data to be share with investigators only.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

